Back to Search
JOHN CORBOY, M.D.
M.D.
Specialist
NPI: 1528405081Individual
Specialties, Licenses & Credentials
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
PMID 37353277·Lancet Neurol·2023
2-rct
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis.
PMID 33990101·Curr Opin Neurol·2021
6-review
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
PMID 31368401·Mult Scler·2020
8-other
Factors that influence adherence with disease-modifying therapy in MS.
PMID 19444532·J Neurol·2009
4-observational
How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis.
PMID 19373561·Neuropsychol Rev·2009
6-review
Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder.
PMID 19287308·J Neuropathol Exp Neurol·2009
5-case
Education research: neurology residency training in the new millennium.
PMID 19171823·Neurology·2009
8-other
Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review.
PMID 18952560·Clin Breast Cancer·2008
5-case
VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis.
PMID 17947712·J Immunol·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 95-717 KIPAPA DR APT 23
MILILANI, HI 96789 - Phone
- (808) 627-0824
Quick Facts
- NPI
- 1528405081
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile